Gayan S De Silva1, Kshitij Desai1, Malik Darwech1, Uzma Naim1, Xiaohua Jin1, Sangeeta Adak2, Nikolai Harroun1, Luis A Sanchez1, Clay F Semenkovich2, Mohamed A Zayed3. 1. (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA. 2. Washington University School of Medicine, Department of Internal Medicine, Division of Endocrinology, Lipid, and Metabolism, St. Louis, MO, USA. 3. (a)Washington University School of Medicine, Department of Surgery, Section of Vascular Surgery, St. Louis, MO, USA; Veterans Affairs St. Louis Health Care System, St. Louis, MO, USA. Electronic address: zayedm@wustl.edu.
Abstract
BACKGROUND AND AIMS: Diabetes is an independent risk factor for carotid artery stenosis (CAS). Fatty acid synthase (FAS), an essential de novo lipogenesis enzyme, has increased activity in the setting of diabetes that leads to altered lipid metabolism. Circulating FAS (cFAS) was recently observed in the blood of patients with hyperinsulinemia and cancer. We thought to evaluate the origin of cFAS and its role in diabetes-associated CAS. METHODS: Patients with diabetes and no diabetes, undergoing carotid endarterectomy (CEA) for CAS, were prospectively enrolled for collection of plaque and fasting serum. FPLC was used to purify lipoprotein fractions, and ELISA was used to quantify cFAS content and activity. Immunoprecipitation (IP) was used to evaluate the affinity of cFAS to LDL-ApoB. RESULTS: Patients with CAS had higher cFAS activity (p < 0.01), and patients with diabetes had higher cFAS activity than patients with no diabetes (p < 0.05). cFAS activity correlated with serum glucose (p = 0.03, r2 = 0.35), and cFAS content trended with plaque FAS content (p = 0.06, r2 = 0.69). cFAS was predominantly in LDL cholesterol fractions of patients with CAS (p < 0.001), and IP of cFAS demonstrated pulldown of ApoB. Similar to patients with diabetes, db/db mice had highest levels of serum cFAS (p < 0.01), and fasL-/- (tissue-specific liver knockdown of FAS) mice had the lowest levels of cFAS (p < 0.001). CONCLUSIONS: Serum cFAS is higher in patients with diabetes and CAS, appears to originate from the liver, and is LDL cholesterol associated. We postulate that LDL may be serving as a carrier for cFAS that contributes to atheroprogression in carotid arteries of patients with diabetes.
BACKGROUND AND AIMS: Diabetes is an independent risk factor for carotid artery stenosis (CAS). Fatty acid synthase (FAS), an essential de novo lipogenesis enzyme, has increased activity in the setting of diabetes that leads to altered lipid metabolism. Circulating FAS (cFAS) was recently observed in the blood of patients with hyperinsulinemia and cancer. We thought to evaluate the origin of cFAS and its role in diabetes-associated CAS. METHODS:Patients with diabetes and no diabetes, undergoing carotid endarterectomy (CEA) for CAS, were prospectively enrolled for collection of plaque and fasting serum. FPLC was used to purify lipoprotein fractions, and ELISA was used to quantify cFAS content and activity. Immunoprecipitation (IP) was used to evaluate the affinity of cFAS to LDL-ApoB. RESULTS:Patients with CAS had higher cFAS activity (p < 0.01), and patients with diabetes had higher cFAS activity than patients with no diabetes (p < 0.05). cFAS activity correlated with serum glucose (p = 0.03, r2 = 0.35), and cFAS content trended with plaque FAS content (p = 0.06, r2 = 0.69). cFAS was predominantly in LDL cholesterol fractions of patients with CAS (p < 0.001), and IP of cFAS demonstrated pulldown of ApoB. Similar to patients with diabetes, db/db mice had highest levels of serum cFAS (p < 0.01), and fasL-/- (tissue-specific liver knockdown of FAS) mice had the lowest levels of cFAS (p < 0.001). CONCLUSIONS: Serum cFAS is higher in patients with diabetes and CAS, appears to originate from the liver, and is LDL cholesterol associated. We postulate that LDL may be serving as a carrier for cFAS that contributes to atheroprogression in carotid arteries of patients with diabetes.
Authors: T M Loftus; D E Jaworsky; G L Frehywot; C A Townsend; G V Ronnett; M D Lane; F P Kuhajda Journal: Science Date: 2000-06-30 Impact factor: 47.728
Authors: Hong Chang Tan; E Shyong Tai; Dmitri Sviridov; Paul J Nestel; Cindy Ng; Edmund Chan; Yvonne Teo; Daniel Chun Hang Wai Journal: J Clin Lipidol Date: 2011-06-28 Impact factor: 4.766
Authors: Manu V Chakravarthy; Irfan J Lodhi; Li Yin; Raghu R V Malapaka; H Eric Xu; John Turk; Clay F Semenkovich Journal: Cell Date: 2009-07-30 Impact factor: 41.582
Authors: P-J Touboul; M G Hennerici; S Meairs; H Adams; P Amarenco; N Bornstein; L Csiba; M Desvarieux; S Ebrahim; R Hernandez Hernandez; M Jaff; S Kownator; T Naqvi; P Prati; T Rundek; M Sitzer; U Schminke; J-C Tardif; A Taylor; E Vicaut; K S Woo Journal: Cerebrovasc Dis Date: 2012-11-01 Impact factor: 2.762
Authors: T W Kuebler; P J Bendick; S E Fineberg; O N Markand; J A Norton; F N Vinicor; C M Clark Journal: Diabetes Care Date: 1983 May-Jun Impact factor: 19.112
Authors: Edward W Gregg; Yanfeng Li; Jing Wang; Nilka Rios Burrows; Mohammed K Ali; Deborah Rolka; Desmond E Williams; Linda Geiss Journal: N Engl J Med Date: 2014-04-17 Impact factor: 91.245
Authors: Shirli Tay; Gayan S De Silva; Connor M Engel; Nikolai Harroun; Amanda S Penrose; Kshitij A Desai; Yan Yan; Clay F Semenkovich; Mohamed A Zayed Journal: Sci Rep Date: 2021-09-29 Impact factor: 4.996